Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.89 USD
+0.36 (6.51%)
Updated Oct 14, 2025 04:00 PM ET
After-Market: $5.88 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RXRX 5.89 +0.36(6.51%)
Will RXRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Other News for RXRX
Is RXRX building bullish momentum? Non-ADX 1,2,3,4 Bullish shows up after climbing 3.95%
Recursion Pharmaceuticals call volume above normal and directionally bullish
Recursion Pharmaceuticals call volume above normal and directionally bullish
Is RXRX setting up for a drop? Fell Below 200 Day Moving Average shows up after tumbling 9.98%
200 Day Moving Average Support appears for RXRX after 2.96% move